AVXL News Alert Anavex Life Sciences (AVXL) 0.1988 12/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anavex Life Sciences (AVXL) 0.1988 $AVXL

Anavex to Present at Biotech Showcase 2015 in San Francisco
GlobeNewswire - Thu Dec 18, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, will present at Biotech Showcase 2015 on Monday January 12, 2015 at 2:00pm PST. The investor and partnering conference will take place at the Parc 55 Wyndham San Francisco - Union Square.

Anavex Begins Enrollment of Alzheimer's Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS
GlobeNewswire - Tue Dec 16, 6:23AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL) today announced enrollment of the first patient in a multicenter Phase 2a clinical trial for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer's disease. The randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX 2-73 alone as well as in combination with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer's disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer's disease. ANAVEX 2-73 showed no serious adverse events in a previously performed Phase 1 study.

Anavex Life Sciences to trade on OTCQX
M2 - Mon Dec 15, 5:50AM CST
OTC Markets Group (OtherOTC:OTCM) disclosed on Friday that Anavex Life Sciences has qualified to trade on OTCQX today under the symbol "AVXL."

Anavex Upgrades to OTCQX Marketplace
GlobeNewswire - Fri Dec 12, 6:11AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announces that the Company is now trading on the OTCQX marketplace under the Company's existing stock ticker AVXL. OTCQX is the best marketplace for established, global and growth companies operated by OTC Markets Group Inc.

OTC Markets Group Welcomes Anavex Life Sciences to OTCQX®
PR Newswire - Fri Dec 12, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp. ("Anavex" (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 340.89 (+5.13), KNMD: (), GSK: 42.85 (+0.11), BCLI: 3.85 (+0.22), CBMG: 12.98 (+0.19), CUR: 2.70 (+0.07)

Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer's
GlobeNewswire - Mon Nov 17, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's, which has shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Observed adverse events included moderate and reversible headache and dizziness, which is common in drugs that target central nervous system (CNS) conditions, including Alzheimer's. No serious side effects were reported in this randomized, double-blind, placebo-controlled study, there was no study discontinuation due to adverse events, ANAVEX 2-73 was found to be safe and well tolerated, and the results indicate a favorable pharmacokinetics profile. Findings from the Phase 1 clinical trial were presented at CNS Summit 2014 in Boca Raton, Florida. A Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept(R)), is now underway.

"New To The Street" Is Back on the Street
Marketwired - Thu Nov 13, 12:40PM CST
"New To The Street" was back on the street in NYC outside the See Thru Equity Conference, seethruequity.com, on 45th Street, interviewing several CEO's who were presenting at the micro-cap conference. We will be featuring these interviews on our website, NewToTheStreet.com on our segment called "On the Street Interviews."
DSKX: 0.69 (+0.01)

SeeThruEquity Initiates Research Coverage on Anavex Life Sciences Corporation with a Price Target of $1.33
ACCESSWIRE - Tue Nov 11, 8:01AM CST
New York, NY / ACCESSWIRE / November 11, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Anavex Life Sciences Corporation (OTCQB: AVXL) with a 12-month price target of $1.33.

Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference
GlobeNewswire - Mon Nov 10, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, is pleased to announce the upcoming presentation of complete Phase 1 clinical trial data for ANAVEX 2-73. The data will be revealed in a poster session at CNS Summit 2014 on November 14th. The poster was co-authored by Ole Voges and Ingo Weigmann of ABX-CRO, Norman Bitterlich of Medizin & Service GmbH, Christoph Schindler of Clinical Research Center, and Christopher U. Missling, President and CEO of Anavex.

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73
PR Newswire - Fri Nov 07, 6:00AM CST
Neuronetrix has been selected by Anavex Life Sciences Corp. (OTCQB: AVXL) to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION(TM) System to measure and analyze cognitive biomarkers in study participants.

Anavex to Present at SeeThruEquity Investor Conference in New York City
GlobeNewswire - Thu Nov 06, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, will be featured at the SeeThruEquity Fall Microcap Investor Conference in New York City. Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, is scheduled to deliver the presentation at the Convene Midtown East on November 12, 2014 at 11:30 AM EST.

Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer's Disease
GlobeNewswire - Mon Nov 03, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) announced today that it has received regulatory approval from the Ethics Committee in Australia to initiate a Phase 2a clinical trial of its proprietary compound, ANAVEX 2-73, as well as ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept). The approved Phase 2a clinical trial is the first study of ANAVEX 2-73 in Alzheimer's patients. The investigational compound targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer's disease. Patient screening and enrollment will now commence. Results are expected in 2015.

Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to Market
GlobeNewswire - Mon Oct 27, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has signed a $500,000 Securities Purchase Agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park" , a long time institutional investor in the Company.

Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles
M2 - Thu Sep 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Takeda Pharmaceutical Company Limited - Glenmark Pharmaceuticals Ltd. - Pfizer Inc. - Evotec AG - Anavex Life Sciences Corp. - Array BioPharma Inc. - Pluristem Therapeutics Inc. - BCN Peptides, S.A. - Upsher-Smith Laboratories, Inc. - Grunenthal GmbH - Integral Molecular, Inc. - AngioChem Inc. - Asahi Kasei Pharma Corp. - Hydra Biosciences, Inc. - NeurAxon, Inc. - Cara Therapeutics, Inc. - CLL Pharma - Dompe Farmaceutici S.p.A. - Lohocla Research Corporation - MAKScientific, LLC - RaQualia Pharma Inc. - Sunovion Pharmaceuticals Inc. - Adynxx, Inc. - Kareus Therapeutics, SA - AnaBios Corporation - Creabilis SA - Istituto Italiano di Tecnologia - Infirst Healthcare Limited - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v4...atory_pain
PSTI: 2.46 (unch), PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86), PTIE: 2.01 (-0.02), ARRY: 4.64 (+0.07)

Anavex Supports Alzheimer's Foundation of America's 3rd Annual Concepts in Care Educational Conference
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced its corporate sponsorship of the upcoming Alzheimer's Foundation of America's 5 Boroughs Concepts in Care Conference. The educational conference, which takes place in New York City at the Sheraton Times Square Hotel on Friday, September 12, 2014, will bring together family caregivers, healthcare professionals and individuals with Alzheimer's disease. Experts in the field are scheduled to make presentations and attendees will receive first-hand perspectives on the medical, behavioral and practical issues faced by people with Alzheimer's disease and those around them.

Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference on Wednesday, September 10, 2014 at 1:40 p.m. ET in the Adams Salon of the New York Palace Hotel. Investors not able to attend in person may view Dr. Missling's presentation via a live webcast, which will also be archived on Anavex's website.

Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer's Clinical Trial
GlobeNewswire - Tue Aug 26, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has selected The Alfred Hospital in Melbourne, Australia as the lead site for its upcoming Phase 2a clinical trial for ANAVEX 2-73, which is being developed as a potential disease-modifying treatment for Alzheimer's disease. In total, the trial will involve up to seven experienced Alzheimer's disease clinical trial sites in Melbourne. The clinical trial, including the commencement of patient recruitment, has been submitted to The Alfred Hospital's Ethics Committee for approval.

Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor
GlobeNewswire - Tue Aug 19, 7:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today new data published in the current issue of Cell Death and Disease that the commonly used selective serotonin reuptake inhibitor (SSRI) Fluvoxamine has a high affinity for sigma-1 receptor (S1R) and thus can alleviate cell stress.

Anavex Reports Fiscal Third Quarter 2014 Financial Results
GlobeNewswire - Wed Aug 13, 6:17AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today reported financial results for the three and nine months ended June 30, 2014.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 48

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 37

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 124

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 60

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 15

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 83

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Millrose Lawsuit Puts Disclosure Discipline in Focus

Updated Category News Views 15

A supposedly clean homesite-option story has wandered into the legal weeds, and that is exactly where investors need to slow down. A shareholder class action against Millrose Properties alleges the company painted one business model for the market while pursuing a materially different one behind the curtain. That allegation has not been proven in court, and anybody...

Continue Reading

Top 5 Most Recently Viewed Articles

LootBar Enhances Game Recharge with New Security Features

Updated Category News Views 193

LootBar Redefines Game Recharge Security As players seek a secure method for discounted game top-ups, LootBar has introduced a groundbreaking self top-up feature. This innovative addition empowers gamers to conduct transactions without exposing their account passwords, presenting a safer alternative to traditional recharge methods. A Major Leap Forward in Security The...

Continue Reading
Marriott Bonvoy Unveils Unique Pet-Friendly Travel Program

Updated Category News Views 406

Introduction to the Pawssible Journey Program Marriott Bonvoy, a beloved travel program from Marriott International, is set to enchant pet owners across Greater China with the introduction of its new initiative called the "Pawssible Journey." This innovative program is founded on three primary experiences: "Paw Stay" themed accommodations, "Paw Play" social interaction...

Continue Reading
Xeriant Unveils Groundbreaking Video Showcasing Fire Safety Innovation

Updated Category News Views 155

Xeriant Highlights Innovative Fire-Retardant Technology in New Video Xeriant, Inc. (OTCQB: XERI), a pioneering company dedicated to the discovery and commercialization of advanced materials technology, has released a fascinating video that dives into the remarkable performance of their nanotech fire-retardant. This video encapsulates the power of their innovative fire...

Continue Reading
Understanding Blackstone's Recent Options Activity and Trends

Updated Category News Views 202

Blackstone's Bullish Options Environment Investors looking at Blackstone are seeing some exciting movements in the options market. These activities have been driven by significant investment interest, hinting that major players are optimistic about Blackstone's future. Insight into Trading Patterns Upon reviewing the trading history for Blackstone (NYSE: BX), multiple...

Continue Reading
Top Smart Meter Startups Spotlight: 360Quadrants Key Report

Updated Category News Views 306

360Quadrants Highlights Smart Meter Startups in 2025 360Quadrants has recently unveiled an insightful report that shines a light on the leading startups and SMEs in the smart meter industry. This comprehensive evaluation showcases both established global players and emerging innovators who are making remarkable strides in market presence, product development, and...

Continue Reading